[go: up one dir, main page]

WO2012006181A3 - Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer - Google Patents

Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer Download PDF

Info

Publication number
WO2012006181A3
WO2012006181A3 PCT/US2011/042436 US2011042436W WO2012006181A3 WO 2012006181 A3 WO2012006181 A3 WO 2012006181A3 US 2011042436 W US2011042436 W US 2011042436W WO 2012006181 A3 WO2012006181 A3 WO 2012006181A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
cancer
treatment
inhibiting oncogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/042436
Other languages
French (fr)
Other versions
WO2012006181A2 (en
Inventor
Josep M. Llovet
Sara Toffanin
Radoslav Savic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of WO2012006181A2 publication Critical patent/WO2012006181A2/en
Publication of WO2012006181A3 publication Critical patent/WO2012006181A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to microRNA inhibitors and methods of use thereof. More particularly, compositions and methods for treating hepatocellular carcinoma using inhibitors of microRNA molecules overexpressed in the chromosome 19q13.41 (C19MC) locus are provided.
PCT/US2011/042436 2010-06-29 2011-06-29 Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer Ceased WO2012006181A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35977010P 2010-06-29 2010-06-29
US61/359,770 2010-06-29

Publications (2)

Publication Number Publication Date
WO2012006181A2 WO2012006181A2 (en) 2012-01-12
WO2012006181A3 true WO2012006181A3 (en) 2012-04-26

Family

ID=45441752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/042436 Ceased WO2012006181A2 (en) 2010-06-29 2011-06-29 Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer

Country Status (1)

Country Link
WO (1) WO2012006181A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9593347B2 (en) 2010-04-16 2017-03-14 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
PT2880053T (en) * 2012-08-01 2020-05-22 Ikaika Therapeutics Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
ES2810800T3 (en) 2013-10-28 2021-03-09 Univ Pittsburgh Commonwealth Sys Higher Education Oncolytic HSV vector
EP3247716A4 (en) 2015-01-20 2018-10-17 Miragen Therapeutics, Inc. Mir-92 inhibitors and uses thereof
KR20180136435A (en) 2016-01-27 2018-12-24 온코루스, 인크. Tumor-like viral vectors and uses thereof
WO2017210735A1 (en) * 2016-06-07 2017-12-14 Garvan Institute Of Medical Research Methods of treating neuroblastoma and reagents therefor
WO2017218689A1 (en) * 2016-06-14 2017-12-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
CA3029426A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
WO2018047148A1 (en) * 2016-09-12 2018-03-15 Novartis Ag Compounds for the inhibition of mirna
CN110603329B (en) * 2017-03-02 2023-12-05 优美佳肿瘤技术有限公司 Methylation markers for diagnosis of hepatocellular carcinoma and lung cancer
SG11202000691XA (en) 2017-07-26 2020-02-27 Oncorus Inc Oncolytic viral vectors and uses thereof
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
CN113917146B (en) * 2020-07-10 2025-10-03 上海吉凯基因医学科技股份有限公司 Uses of human POLE2 gene and related products
CN114480399A (en) * 2022-03-17 2022-05-13 江苏医药职业学院 siRNA for reducing CPB1 gene expression, recombinant vector and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105174A1 (en) * 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
US20090220589A1 (en) * 2008-03-01 2009-09-03 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
US20090226375A1 (en) * 2008-02-21 2009-09-10 Eric Olson MICRO-RNAs THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION AND USES THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105174A1 (en) * 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
US20090226375A1 (en) * 2008-02-21 2009-09-10 Eric Olson MICRO-RNAs THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION AND USES THEREOF
US20090220589A1 (en) * 2008-03-01 2009-09-03 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RIPPE ET AL.: "The Two Stem Cell MicroRNA Gene Clusters C19MC and miR-371-3 Are Activated by Specific Chromosomal Rearrangements in a Subgroup of Thyroid Adenomas.", PLOS ONE, vol. 5, no. 3, 3 March 2010 (2010-03-03), pages 1 - 11, XP002607044, DOI: doi:10.1371/JOURNAL.PONE.0009485 *
TOFFANIN ET AL.: "MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a", GASTROENTEROLOGY, vol. 140, no. 5, May 2011 (2011-05-01), pages 1618 - 1628 *

Also Published As

Publication number Publication date
WO2012006181A2 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
WO2012006181A3 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
WO2012103059A3 (en) Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
MX360404B (en) Compounds for inhibiting cell proliferation in egfr-driven cancers.
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
IL205307A0 (en) Targeting micrornas for the treatment of liver cancer
SI2358697T1 (en) Isoindoline compounds for use in the treatment of cancer.
WO2009137462A3 (en) Methods for treating cognitive disorders using inhibitors of histone deacetylase
WO2010045345A3 (en) Treatment method
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
NZ626359A (en) Antisense molecules and methods for treating pathologies
PL2340042T3 (en) Methods and compositions for the treatment of cancer
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
WO2012054862A9 (en) Agents, compositions, and methods for treating pruritis and related skin conditions
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2009114703A3 (en) Combination therapy for the treatment of cancer
EP2224919A4 (en) Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
NZ723971A (en) Methods and compositions for treating ewings sarcoma family of tumors
WO2008086182A3 (en) Use of gene signatures to design novel cancer treatment regimens
WO2008092099A8 (en) Compositions and methods for treating hematopoietic malignancies
HK1210049A1 (en) Combination therapies for treating cancer
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
WO2015032800A3 (en) Compositions and methods for inducing senescence in cancer cells
WO2012170742A3 (en) Treatment and prevention of cancer with hmgb1 antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11804199

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11804199

Country of ref document: EP

Kind code of ref document: A2